Biogen Entered into a Commercialization and License Agreement to Develop & Commercialize Xcimzane, a Proposed Biosimilar Referencing Cimzia (certolizumab pegol)
Shots:
- Xbrane to receive $8M up front, $80M in milestone upon achievement of development and commercial milestones & is also eligible to receive royalties
- Biogen to get exclusive global regulatory, manufacturing, and commercial rights to Xcimzane and will be the marketing authorization holder
- Xbrane will be responsible for the completion of pre-clinical development of Xcimzane while Biogen lead the remaining development activities and costs to achieve marketing authorization in all territories including those for clinical development
Ref: Globe Newswire | Image:Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
